Reviewing Agios Pharmaceuticals (AGIO) and Its Peers
Agios Pharmaceuticals (NASDAQ: AGIO) is one of 291 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Agios Pharmaceuticals to similar companies based on the strength of its valuation, profitability, institutional ownership, dividends, analyst recommendations, earnings and risk.
Earnings and Valuation
This table compares Agios Pharmaceuticals and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Agios Pharmaceuticals||$69.89 million||-$198.47 million||-12.81|
|Agios Pharmaceuticals Competitors||$290.27 million||$35.99 million||68.50|
Volatility & Risk
Agios Pharmaceuticals has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals’ peers have a beta of 0.27, suggesting that their average stock price is 73% less volatile than the S&P 500.
This is a breakdown of recent ratings and price targets for Agios Pharmaceuticals and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Agios Pharmaceuticals Competitors||1176||3523||12063||248||2.67|
Agios Pharmaceuticals presently has a consensus target price of $77.00, suggesting a potential downside of 4.10%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 32.86%. Given Agios Pharmaceuticals’ peers higher probable upside, analysts clearly believe Agios Pharmaceuticals has less favorable growth aspects than its peers.
This table compares Agios Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Agios Pharmaceuticals Competitors||-5,345.53%||-158.67%||-35.84%|
Insider and Institutional Ownership
82.7% of Agios Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.1% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.